HanAll, Daewoong and NurrOn Complete First Human Parkinson’s Therapy Study
Details : HL192(ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, it is being investigating for treating Parkinson's Disease.
Product Name : HL192
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 25, 2024
Angelini Pharma Signs Option Agreement with Cureverse for Brain Health Asset
Details : Under the agreement, Angelini Pharma will lead all the development efforts for CV-01, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases.
Product Name : CV-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 21, 2024
Oscotec/ADEL Doses First Patient in Phase 1 for ADEL-Y01 in Alzheimer’s Disease
Details : ADEL-Y01 is a recombinant IgG1 class type monoclonal humanized antibody that binds to tau protein acetylated at lysine-280, which is investigated for the treatment of alzheimer's disease.
Product Name : ADEL-Y01
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 23, 2024
Details : HL192 (ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, a master regulator associated with the development and maintenance of dopaminergic neurons, for the potential treatment of Parkinson's Disease.
Product Name : HL192
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2023
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
Details : OLP-1002 manifested excellent safety in a UK Phase 1 study evaluated in a total of 116 healthy volunteers. In the meantime, an exploratory Phase 1b study in Australia suggested clues to strong efficacy and long therapeutic duration in OA patients.
Product Name : OLP-1002
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
October 25, 2021